[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100283644":3},{"organization":4,"armGroups":7,"interventions":38,"overallOfficials":58,"centralContacts":44,"locations":62,"responsibleParty":86,"collaborators":44,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":44,"eligibilityCriteria":94,"healthyVolunteers":95,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":44,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":44,"overallStatus":108,"whyStopped":44,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",[8,14,20,24,28,33],{"label":9,"type":10,"description":11,"interventionNames":12},"Part I: RO7079901","EXPERIMENTAL","Participants will be randomized in two dose cohorts to receive single dose of RO7079901 1000 and 2000 milligrams (mg) intravenous (IV) infusion on Days 1 through Day 7 every 8 hours (q8h), for a total of 19 doses, with the last dose administered on the morning of Day 7.",[13],"Drug: RO7079901",{"label":15,"type":16,"description":17,"interventionNames":18},"Part I: Placebo","PLACEBO_COMPARATOR","Participants will be randomized in two dose cohorts to receive single dose of placebo matching to RO7079901 on Days 1 through Day 7 q8h, for a total of 19 doses, with the last dose administered on the morning of Day 7.",[19],"Other: RO7049389 Placebo",{"label":21,"type":10,"description":22,"interventionNames":23},"Part II - Single Dose and Repeat Dose: RO7079901","Participants will be randomized in two dose cohorts to receive single dose of RO7079901 IV infusion at a dose above the previously studied dose levels in Part I (greater than \\[\\>\\] 2000 mg) on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.",[13],{"label":25,"type":16,"description":26,"interventionNames":27},"Part II - Single Dose and Repeat Dose: Placebo","Participants will be randomized in two dose cohorts to receive single dose placebo matching to RO7079901 on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.",[19],{"label":29,"type":10,"description":30,"interventionNames":31},"Part III: RO7079901 + Meropenem","Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem IV infusion in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of 2000 mg meropenem IV infusion on Day 1. On Day 2, participants will receive a single dose of RO7079901 IV infusion. Participants randomized to Sequence 2 will receive a single dose of RO7079901 IV infusion on Day 1. On Day 2, participants will receive a single dose of 2000 mg meropenem IV infusion. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 in combination with meropenem IV infusion q8h, regardless of sequence. Escalation to a maximum dose of RO7079901 5000 mg q8h may be considered on the basis of safety and tolerability data from the previous cohorts.",[13,32],"Drug: Meropenem",{"label":34,"type":16,"description":35,"interventionNames":36},"Part III: RO7079901 Placebo + Meropenem Placebo","Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem matching placebos in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of placebo matching to meropenem on Day 1. On Day 2, participants will receive a single dose of placebo matching to RO7079901. Participants randomized to Sequence 2 will receive a single dose of placebo matching to RO7079901 on Day 1. On Day 2, participants will receive a single dose of placebo matching to meropenem. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 and meropenem matching placebos q8h, regardless of sequence.",[19,37],"Other: Meropenem Placebo",[39,45,49,54],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"DRUG","RO7079901","RO7079901 will be administered as per schedule described in individual arm.",[9,21,29],null,{"type":40,"name":46,"description":47,"armGroupLabels":48,"otherNames":44},"Meropenem","Meropenem will be administered as per schedule described in individual arm.",[29],{"type":50,"name":51,"description":52,"armGroupLabels":53,"otherNames":44},"OTHER","RO7049389 Placebo","Placebo matching to RO7049389 will be administered as per schedule described in individual arm.",[15,25,34],{"type":50,"name":55,"description":56,"armGroupLabels":57,"otherNames":44},"Meropenem Placebo","Placebo matching to meropenem will be administered as per schedule described in individual arm.",[34],[59],{"name":60,"affiliation":5,"role":61},"Clinical Trials","STUDY_DIRECTOR",[63,76],{"facility":64,"status":44,"city":65,"state":66,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":44},"Covance Clinical Research Unit Inc.; Covance Gfi Research","Evansville","Indiana","47710","United States","US",{"type":71,"coordinates":72},"Point",[73,74],-87.55585,37.97476,{"lat":74,"lon":73},{"facility":77,"status":44,"city":78,"state":79,"zip":80,"country":68,"countryCode":69,"cosmosGeoPoint":81,"geoPoint":85,"contacts":44},"Covance Clinical Research Unit, Inc","Madison","Wisconsin","53704",{"type":71,"coordinates":82},[83,84],-89.40123,43.07305,{"lat":84,"lon":83},{"type":87,"investigatorFullName":44,"investigatorTitle":44,"investigatorAffiliation":44,"oldNameTitle":44,"oldOrganization":44},"SPONSOR","100283644","phase-1-a-study-to-investigate-the-safety-tolerability-and-pharmacokinetics-of-ro7079901-and-the-combination-of-ro7079901-with-meropenem-in-adult-healthy-volunteers-100283644",false,"NCT02972255","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers","A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of RO7079901 Administered Intravenously Both Alone and in Combination With Meropenem in Adult Healthy Volunteers","Inclusion Criteria:\n\n* Healthy male or healthy female of non-childbearing-potential\n* A Body Mass Index (BMI) between 18.0 and 30.0 kilograms per square meter (kg\u002Fm\\^2) (inclusive) and a body weight of at least 45 kilograms (kg) at screening\n* Negative urine drug and alcohol screen (barbiturates, benzodiazepines, methadone, amphetamines, methamphetamines, opiates, cocaine, cannabinoids, cotinine, and alcohol)\n* Non-smokers, or former smokers, who have not smoked for at least 60 days prior to screening\n\nExclusion Criteria:\n\n* Known history of any significant hypersensitivity or severe allergic reaction to any beta-lactam antibiotics (e.g., cephalosporins, penicillins, carbapenems, or monobactams)\n* History of any severe antibiotic-associated superinfections like Clostridium difficile colitis and\u002For frequent fungal vaginal infections\n* Concurrent or history of clinically significant cardiovascular, hepatic, renal, endocrine, gastrointestinal, respiratory, psychiatric, neurologic, and\u002For hematological disorders\n* A history or presence of malignancy (with the exception of successfully treated basal cell carcinoma); seizures, brain lesions or other significant neurological diseases\n* Donation of blood (or loss of blood) greater than 500 milliliters (mL) within three months before screening\n* History of Gilbert syndrome\n* Any clinically significant concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the healthy volunteer in this study\n* Positive test at screening of any of the following: Hepatitis A Virus Immunoglobulin M Antibody (HAV IgM Ab), Hepatitis B Surface Antigen (HBsAg), Hepatitis C Virus Ribonucleic Acid or Hepatitis C Virus Antibody (HCV RNA or HCVAb), or Human Immunodeficiency Virus Antibody (HIV Ab)",true,"ALL","18 Years","70 Years",{"count":100,"type":101},46,"ACTUAL","INTERVENTIONAL",[104],"PHASE1","This is a randomized, double-blind, placebo-controlled, multiple-ascending dose (MAD) study that will evaluate the safety, tolerability and pharmacokinetics (PK) of RO7079901 and the combination of RO7079901 with meropenem in healthy volunteers. The study will consist of three parts (Part I, II, and III). At each dose level\u002Fcohort, a total of 8 healthy volunteers will be randomized to receive active study drug or placebo in a 3:1 ratio.",[107],"Healthy Volunteers","COMPLETED","2017-05-18",{"date":111,"type":101},"2017-05-19",{"date":113,"type":101},"2016-10-31",{"date":115,"type":101},"2017-03-24",{"name":5,"class":6},2]